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Abstract
Background: Disturbances in leptin and insulin signaling pathways are related to obesity and metabolic syndrome
(MS) with increased risk of diabetes and cardiovascular disease. Janus kinase 2 (JAK2) is a tyrosine kinase involved
in the activation of mechanisms that mediate leptin and insulin actions. We conducted a population cross-sectional
study to explore the association between two common variants in JAK2 gene and MS related traits in 724
Argentinean healthy male subjects.
Methods: A total of 724 unrelated men aged 37.11 ± 10.91 yr were included in a cross-sectional study. Physical
examination, anthropometric measurements and biochemical analysis were determined by a standardized protocol.
rs7849191 and rs3780378 were genotyped. Analyses were done separately for each SNP and followed up by
haplotype analysis.
Results: rs7849191 and rs3780378 were both associated with reduced risk of MS [p = 0.005; OR (95%CI) = 0.52
(0.33-0.80) and p = 0.006; OR (95% CI) = 0.59 (0.40-0.86) respectively, assuming a dominant model]. rs3780378 T
allele was associated with triglyceridemia values under 150 mg/dl [p = 0.007; OR (95%CI) = 0.610 (0.429-0.868)] and
TT carriers showed lower triglycerides (p = 0.017), triglycerides/HDL-C ratio (p = 0.022) and lipid accumulation
product (p = 0.007) compared to allele C carriers. The two-SNPs-haplotype analysis was consistent with single locus
analysis.
Conclusions: It was found for the first time, significant associations of JAK2 common variants and related
haplotypes with reduced risk of MS. These findings could be explained by the role of JAK2 in insulin and/or leptin
signaling.
Background
The metabolic syndrome (MS) is a constellation of car-
diometabolic risk factors including central obesity, insu-
lin resistance (IR), hypertension, hyperglycemia, and
dislipidemia [1,2]. Insulin resistance (IR) is probably the
principal cause of the MS [3,4]. Over the past decades, a
sustained worldwide increase in the incidence of MS has
taken place, associated with the global epidemic of obe-
sity and type 2 Diabetes Mellitus (DM2) [5].
Janus kinase 2 (JAK2) is a nonreceptor tyrosine kinase
recruited by receptors that lack intrinsic kinase activity
[6]. The JAK/STAT (signal transducer and activator of
transcription) pathway transmits a wide range of cyto-
plasmic signals from cytokines, growth factors and hor-
mones that bind to specific cell surface receptors [7].
Suppressor of cytokine signaling (SOCS) proteins are
known to act as negative regulators of cytokine action
via inhibition of these pathways. There is a growing
body of evidence that supports a role for specific SOCS
members in the development of IR [8].
Insulin and leptin are major signals to regulate energy
homoeostasis and body adiposity [9,10]. After binding to
its receptor, leptin induces activation of JAK2 and
* Correspondence: pufetin@gmail.com
† Contributed equally
1Humoral Immunity Institute “Prof. Ricardo A. Margni” (IDEHU), National
Research Council (CONICET) & Chair of Immunology, School of Pharmacy
and Biochemistry, University of Buenos Aires (UBA) - Argentina
Full list of author information is available at the end of the article
Penas-Steinhardt et al. BMC Medical Genetics 2011, 12:166
http://www.biomedcentral.com/1471-2350/12/166
© 2011 Penas-Steinhardt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.subsequent phosphorylation of specific tyrosines on the
receptor [11]. The cytokine-like hormone leptin receptor
is a member of the class I cytokine receptor family
found in many tissues in several alternatively spliced
forms [12,13]. The long isoform (LepRb) transduces sig-
nal mainly through the JAK2/STAT3 pathway. JAK2
also phosphorylates Insulin Receptor Substrates 1 and 2
(IRS-1 and IRS-2) integral to insulin and leptin action
[14]. Insulin carries out its biological effects through the
phosphorylation of IRS-1 and IRS-2 and it is also well
documented the cross-talk between the insulin and lep-
tin signal transduction pathways. Leptin was reported to
induce IRS-1 and IRS-2 phosphorylation [15].
Recently, although not significant at levels which took
account of multiple testing, suggestive associations
between two single nucleotide polymorphisms (SNPs) of
JAK2 gene and central fat, waist circumference and
serum lipid variables have been reported [16]. Replica-
tion is fundamental for deciding that an observed asso-
ciation is likely not due to chance [17]. Therefore, the
aim of this study was to explore associations between
these two SNPs of JAK2 and their predicted haplotypes
on MS and related phenotypes and quantitative meta-
bolic traits.
Methods
Subjects
The total sample includes 724 unrelated men of self-
reported European ancestry, especially from Spain and
Italy, living in Buenos Aires metropolitan area. Indivi-
duals were selected from a cross-sectional study. Partici-
pants were recruited, between April 2006 and April
2008, from the Departement of Haemotherapy of the
Hospital “José de San Martín” o ft h eU n i v e r s i t yo fB u e -
nos Aires. Ages ranged between 18 to 65 years. Clinical
characteristics of the samplea r es h o w ni nT a b l e1 .A l l
subjects were non diabetic with normal findings on
medical examination and blood count. This work was
carried out in accordance with the Declaration of Hel-
sinki, and approved by the Ethic Committee of our Hos-
pital. All subjects gave their written consent previously
to participate in the study (clinical characteristics are
summarized in Table 1).
Clinical measurements
Anthropometric measurements (height, weight and waist
circumference) and Systolic (SBP) and Diastolic (DBP)
blood pressure were determined by a standardized pro-
tocol in every subject.
After a 12-h overnight fast, fasting blood samples were
drawn in every individual from an antecubital vein. Total
cholesterol (TC), triglycerides (TG), and high-density lipo-
protein (HDL-C) were determined in serum by enzymatic
methods using commercial kits (Roche Diagnostics,
Mannheim, Germany) in a Hitachi 727 autoanalyzer. All
determinations were performed using standardized proce-
dures. Intra assay-CV (coefficient of variation) for TG and
total cholesterol were 1.3 and 1.1%, respectively. Inter
assay-CVs were 2.4% and 1.5%, respectively. Fasting
plasma glucose (FPG) was determined by a glucose-oxi-
dase method (Roche Diagnostics, Mannheim, Germany) in
a Hitachi 727 autoanalyzer. Intra- and inter-CVs were 0.9
and 1.8%, respectively. Fasting serum insulin was mea-
sured by radioimmunoassay with a commercial kit
(Human Insulin Specific RIA kit, Linco Research Inc., St.
Louis, MO, USA) by counting on a gamma counter (DPC
Gambyt CR, Los Angeles, USA), with a lower detection
limit of 2 μU/ml, intra- and inter-CVs being < 1 and <
7.43%, respectively. Cross-reactivity was less than 0.2% to
intact human proinsulin.
Calculations
Insulin sensitivity was assessed with Homeostasis Model
Assessment of insulin resistance (HOMA-IR) using the
software HOMA Calculator v.2.2.2 for Windows [18]
Low-density lipoprotein cholesterol (LDL-C) was calcu-
lated using the Friedewald formula [19]. In addition,
TG/HDL-C ratio and lipid accumulation product (LAP)
were calculated. LAP, an index of lipid overaccumula-
tion associated with cardiovascular risk and identifica-
tion of diabetes, was defined (for men) as (waist
circumference (WC) [cm] - 65) × (TG concentration
[mmol/L]) [20].
Each subject was assessed for the presence of 1) Obe-
sity according to body mass index (BMI) ≥ 30.0 kg/m
2
Table 1 Clinical characteristics of the sample
Mean SD Phenotype Prevalence (%)
Age (yr) 37.11 10.91 HTG 31.1
BMI (kg/m2) 28.20 4.40 HW 27.8
WC (cm) 96.15 12.26 Decreased HDL-C 45.6
SBP (mmHg) 126.29 11.02 Abdominal obesity 31.3
DBP (mmHg) 80.11 7.38 Obesity 29.3
TC (mg/dl) 187.45 40.75 IFG 18.0
LDL-C (mg/dl) 118.52 34.89 MS 24.1
HDL-C (mg/dl) 41.25 10.66
TG (mg/dl) 138.77 95.97
LAP 52.74 6.72
TG/HDL-C 3.86 3.73
FPG (mg/dl) 91.87 12.23
Fasting insulin 16.18 9.27
HOMA-IR 2.07 1.16
n = 724. DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C,
high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment
of insulin resistance; HW, hypertriglyceridemic waist; IR, insulin resistance; LDL-
C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total
cholesterol; TG, triglycerides; LAP = lipid accumulation product; WC, waist
circumference; HTG = Hypertriglyceridemia; HW = hypertriglyceridemic waist;
IFG = impaired fasting glucosa; MS = metabolic syndrome
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Page 2 of 7[21]; 2) abdominal obesity according to WC > 102 cm
[22]; 3) hypertriglyceridemia (HTG) according to fasting
TG ≥150 mg/dl or drug treatment; 4) hypertriglyceri-
demic waist (HW) according to TG ≥ 150 mg/dl + WC
≥ 90 cm; 5) decreased HDL-C according to fasting
HDL-C < 40 mg/dl or drug treatment; 6) Impaired Fast-
ing Glucose (IFG) according to Fasting Plasma Glucose
(FPG) ≥ 100 mg/dl; and 7) MS using the American
Heart Association/National Heart, Lung, and Blood
Institute (AHA/NHLBI) 2005 criteria [23]. Participants
who had FPG ≥ 1 2 6m g / d lw e r ee x c l u d e df r o mt h e
study [24].
SNP selection and genotyping
Since replication of findings is an important require-
ment for genetic association studies, we studied two
SNPs (rs7849191 and rs3780378) based on a previous
report of Ge et al [16]. The linkage disequilibrium (LD)
analysis (Haploview 4.1 [25]) of the 142.8 kb region
under study showed that both SNPs capture 20% of
alleles with minor allele frequency (MAF) ≥ 10% at r
2 ≥
0.8 [we downloaded information from The International
HapMap Project web site (http://www.hapmap.org)
(HapMap Data Rel 28 PhaseII+III, August10) from the
Caucasian European Utah dataset (CEPH)]. Of note,
rs7849191 is not in LD with other SNPs and rs3780378
is in LD with other 17 SNPs (rs2230724, rs4372063,
rs10815144, rs7037207, rs2149556, rs1328918,
rs7034753, rs7875908, rs10115312, rs7023146,
rs7857730, rs7847294, rs6476939, rs7032785, rs7043371,
rs1328917, rs3780378).
Genomic DNA was isolated from peripheral blood
according to standard procedures. The two SNPs were
genotyped by KBiosciences, Hoddesdon, Herts., UK,
using the KASPar system. This is a fluorescence based
allele-specific PCR procedure with improved robustness
and discriminating power over conventional ARMS,
(http://www.kbioscience.co.uk/chemistry/chemistry-
intro.htm). Genotyping accuracy was assessed by inclu-
sion of duplicates and negative controls. Genotyping
success rate was 100% for rs7849191 and 98.7%
rs3780378. Our lab randomly sampled 10% of the sub-
jects for sequencing to corroborate the initial findings.
Using these criteria consistency was 100%.
For each individual case-control study power estima-
tions were performed for single-point allelic effects, with
an odds ratio of 1.5 at a nominal significance level of
0.05 [26]. Power estimation was found to be less than
80% to detect effects on MS. However, to detect effects
on HTG, HW, obesity or abdominal obesity, power esti-
mation was found to be between 81 and 99% assuming
a dominant model and less than 80% assuming a reces-
sive model for rs7849191; and between 80 and 98%
assuming a recessive model and less than 80% assuming
a dominant model for rs3780378. The power estimation
was found to be between 85 and 99% to detect effects of
rs7849191 and rs3780378 on decreased HDL-C.
Statistical analysis
Deviation of the genotype distribution from the Hardy-
Weinberg equilibrium (HWE) was tested using Chi
square (c
2) test. We calculated odds ratio (OR) and 95%
confidence intervals (95%CI). Analyses were done sepa-
rately for each SNP and followed up by haplotype analy-
sis. For individual SNP the statistical difference in
genotype distribution and allele frequencies among the
groups for qualitative variables was assessed by the
Fisher exact test. Binary logistic regression was used to
adjust for possible confounding variables. Quantitative
data were expressed as means ± SD. For comparison of
continuous variables we conducted one-way ANOVA
with Levine’s Test for equality of variances. Otherwise,
we used Welch tests. Multiple linear regression analysis
was used to adjust for possible confounding variables.
Furthermore, genotype status and age subgroup (2 sub-
groups according to the average age: < 37 and ≥37 years
old) were used as factors in a Multivariate linear regres-
sion analysis to determine interaction of age and
genotype.
We reconstructed the two SNP -haplotypes using
PHASE 2.1 [27]. The haplotype frequencies were esti-
mated using the programs PHASE 2.1 and Thesias
[28,29] We analyzed haplotypic effects using the Thesias
software and conventional statistical methods as well. A
Fisher exact test was used to compare haplotype fre-
quencies. The effects of a particular haplotype load (0:
no copies of the particular haplotype; 1: 1 copy; and 2: 2
copies) on continuous variables were tested using a lin-
ear regression.
A two sided p-value less than 0.05 was considered sta-
tistically significant. Since our results represent a basic
replication of previously reported findings, p-values
were not corrected for the number of tests performed.
However, we follow the recommendations of van den
Oord and Sullivan [30], which suggest that a level of sig-
nificance of p = 0.01 on average control the false discov-
ery rate at 0.10. Note that after applying the Bonferroni
correction for multiple tests, the significance level was p
< 0.025 (0.05/2 for 2 loci). The significance level was p
< 0.01 (0.05/4) for correction for multiple tests in haplo-
type analyses (4 haplotypes for 2 loci). Statistical ana-
lyses were conducted using the program for Statistical
Package for the Social Sciences, version 12.0 for Win-
dows (SPSS, Inc., Chicago, IL).
Results
Both rs7849191 (c
2 = 1.52, p = 0.22) and rs3780378 (c
2
=0 . 0 8 6 ,p=0 . 7 7 )w e r ei nH W E .G e n o t y p i cf r e q u e n c i e s
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0.15; and rs3780378: TT 0.26 TC 0.49 and CC 0.25. The
MAFs were 0.037 and 0.49 for rs7849191 and rs3780378
respectively, similar to previously reported in Caucasians
(http://www.ncbi.nlm.nih.gov/snp/).
Single-Locus Analyses
Association with MS
SNPs rs7849191 and rs3780378 were both associated
with MS. Age adjusted association between rs7849191
and MS was not significant, but association between
rs3780378 and MS remained significant taking into
account the effects of age (p = 0.002). C allele of
rs7849191 and T allele of rs3780378 showed a lower
risk for MS assuming both dominant and recessive
model. Adjusted analysis confirmed these associations
(Table 2). Note that associations with MS with both
rs7849191 and rs3780378 under a dominant model,
even accounting for the effects of covariates, were sig-
nificant at levels that take into account multiple
testing.
Association with phenotypes and quantitative traits
related to lipid metabolism
SNP rs3780378 was associated with TG values under
150 mg/dl (p = 0.013 and p = 0.006 after adjusting for
age). T allele carriers showed a lower risk for HTG than
the CC genotype carriers (OR = 0.61 [95% CI = 0.43-
0.87]) at levels that take into account multiple testing
even after correcting for covariates. Furthermore,
rs3780378 was associated with HW (p = 0.037 and p =
0.021 after controlling for age). Moreover, rs3780378T
carriers, assuming both a dominant and a recessive
model, showed lower risk of HW with borderline nom-
inal significance. Age-adjusted analysis confirmed a sig-
nificant effect on HW risk (Table 2).
We also were able to show significant differences
between rs3780378 genotypes in TG (p = 0.001), TG/
HDL-C ratio (p = 0.004) and LAP (p = 0.003). How-
ever, these observations were not confirmed taking
into account the effects of age (Table 3). TT genotype
carriers of rs3780378 compared to allele C carriers
(recessive model), showed a lower TG, LAP and TG/
HDL-C ratio. Adjusted analysis confirmed the associa-
t i o n sa tl e v e l st h a tt a k ei n t o account multiple testing
(Table 3). Associations under a dominant model were
significant only taking into account age (data not
shown).
The association of rs3780378 genotype with TG, LAP
and TG/HDL-C was not age-dependent (p = 0.059, p =
0.213 and p = 0.111 for rs3780378 genotype- by-age
interaction respectively).
The SNP rs3780378 was not associated with HDL-C
or LDL-C. rs7849191 was not associated with categorical
or continuous variables related to lipid metabolism.
Association with obesity and obesity-related quantitative
traits
We found neither associations between both SNPs
under study and obesity or abdominal obesity; nor we
were able to show significant differences among geno-
types in BMI, WC, fasting insulin or HOMA-IR.
Table 2 Association between individual JAK2 SNPs, Metabolic Syndrome and related phenotypes
MS negative MS positive OR (IC 95%) p p
a p
b
rs7849191
TT vs. TC vs. CC 69 vs. 241 vs. 226 38 vs. 76 vs. 57 - 0.009 ns ns
CC + CT vs. TT 467 vs. 69 133 vs. 38 0.517 (0.333-0.803) 0.005 0.001 0.002
CC vs. CT + TT 226 vs. 310 57 vs. 114 0.686 (0.478-0.984) 0.048 0.011 0.034
rs3780378
TT vs. TC vs. CC 149 vs. 269 vs. 121 33 vs. 83 vs. 57 - 0.008 0.002 ns (0.096)
TT +TC vs. CC 418 vs. 121 116 vs. 57 0.589 (0.404-0.858) 0.006 0.001 0.007
TT vs. TC+ CC 149 vs. 390 33 vs. 140 0.617 (0.404-0.942) 0.027 0.020 0.022
HTG negative HTG positive OR (IC 95%) p p
a p
b
rs3780378
TT vs. TC vs. CC 139 vs. 250 vs. 108 48 vs.108 vs. 71 - 0.013 0.006 ns (0.082)
TT +TC vs. CC 389 vs. 108 136 vs. 71 0.610 (0.429-0.868) 0.007 0.002 0.011
TT vs. TC+ CC 139 vs. 358 48 vs. 179 - ns ns
HW negative HW positive OR (IC 95%) p p
a p
b
rs3780378
TT vs. TC vs. CC 145 vs. 257 vs. 118 41 vs.101 vs. 61 - 0.037 0.021 ns (0.082)
TT +TC vs. CC 402 vs. 118 142 vs. 61 0.683 (0.475-0.983) 0.044 0.016 ns (0.07)
TT vs. TC+ CC 145 vs. 375 41 vs. 172 0.655 (0.442-0.969) 0.037 0.033 ns (0.05)
a Age adjusted;
b Age and BMI adjusted. MS = metabolic syndrome; HTG = Hypertriglyceridemia; HW = hypertriglyceridemic waist; ns = not significant.
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The inferred two-SNP-haplotype frequencies of
rs7849191 and rs3780378 in that order were as follow:
CC 0.18, haplotype CT 0.45, haplotype TC 0.32 and
haplotype TT 0.05. In order to reduce the degree of
freedom, the TT haplotype, with a frequency less than
5%, was removed from the analysis. We found 2-df asso-
ciation with MS (p = 0.011) when compared the overall
frequency differences across three possible two-SNP-
haplotypes. We could not find any other significant 2-df
association. In a separate analysis, each haplotype was
compared with haplotype TC. Haplotype CT (carring
both protective alleles) was associated with MS even
taking into account correction for multiple comparisons
(CT vs. TC p = 0.00054, age adjusted p = 0.000071 and
age and BMI adjusted p = 0.00010). Besides, significant
difference in haplotype frequencies was found for TG
values under 150 mg/dl (CT vs. TC p = 0.0069 and CC
vs. TC p = 0.040) and HW (CT vs. TC; p = 0.047 and
CC vs. TC p = 0.0058). Adjusted analysis confirmed
these associations (TG values under 150 mg/dl: CT vs.
TC age adjusted p = 0.026 and age and BMI adjusted p
= 0.0055; CC vs. TC age adjusted p = 0.0023 age and
B M Ia d j u s t e dp=0 . 0 6 8 ;a n dH W :C Tv s .T Ca g e
adjusted p = 0.019 and age and BMI adjusted p = 0.047;
CC vs. TC age adjusted p = 0.0029 and age and BMI
adjusted p = 0.010). No association was found between
the inferred two -SNP-haplotype and another obesity or
lipid metabolism related phenotypes.
Two-SNP haplotype analysis of quantitative metabolic
traits showed association of haplotype CT with TG (CT
vs. TC p = 0.042, age adjusted p = 0.024 and age and
BMI adjusted p = 0.023) and TG/HDL-C ratio (CT vs.
T Cp=0 . 0 1 9 ,p=0 . 0 4 4a n da g ea n dB M Ia d j u s t e dp=
0.027). Association remained significant after adjust-
ment. Association of haplotype CT with LAP became
significant only after age adjustment (CT vs. TC p =
0.059, age adjusted p = 0.061 and age and BMI p =
0.017) and besides, association of haplotype CC with
LAP was observed (CC vs. TC p = 0.042, age adjusted p
=0 . 0 4 8a n da g ea n dB M Ip=0 . 0 4 0 ) .N oa s s o c i a t i o n
between another two-SNP haplotype and continuous
variable related to obesity or lipid metabolism became
apparent.
Although rs7849191 and rs3780378 are located in
intronic regions, possible functional implications worth
further investigation. The studied variants or even those
that are in LD with rs3780378 may affect regulatory
regions that modify the expression of genes playing
roles as genetic modifiers, therefore we used the pro-
gram FASTSNP [31] to investigate potential functional
significance. The analysis revealed that both rs7849191
and rs3780378, and 7 SNPs in LD with rs3780378
(rs10115312, rs7034753, rs7023146, rs7043371,
rs1328917, rs7857730 and rs6476939), may have a possi-
ble effect of intronic enhancer.
For identification of regulatory sequences based in
evolutionarily conserved noncoding regions we per-
formed a human/mouse whole genome comparison
using the BLASTz and ‘subsetAxt’ programs, as
described in the ensembl multicontig view help page.
The results indicate that both rs7849191 and rs3780378
and at least 4 SNPs in LD (rs7037207, rs7875908,
rs2230724, rs6476939) would be located in conserved
regions of 1004 pb, 9977 pb, 2433 pb, 825 pb and 1411
pb respectively.
Discussion
We examined the association between two SNPs of
JAK2 and MS, phenotypes and quantitative traits related
t oM Si nas a m p l eo f7 2 4u n r e l a t e dm e n .B o t h
rs7849191 and rs3780378 were associated with MS
reduced risk at levels that take into account multiple
testing. A p-value to account for multiple hypothesis
testing was taken pragmatically at 0.01 as described in
Statistical Analysis section. Also, we observed
Table 3 Single locus analysis of quantitative metabolic traits and surrogate measures of IR
rs3780378
TT ( n = 186) TC (n = 358) CC (n = 179)
Mean ± SD Mean ± SD Mean ± SD p p
a p
b
TG (mg/dL) 120.61 ± 67.76 144.04 ± 104.745 150.17 ± 106.38 0.001
c ns ns
TG/HDL-C 3.27 ± 2.60 3.99 ± 3.84 4.39 ± 4.68 0.004
c ns ns
LAP 44.42 ± 37.72 54.58 ± 49.32 58.89 ± 50.77 0.003
c ns ns
TT ( n = 187) TC + CC (n = 537)
Mean ± SD Mean ± SD p p
a p
b
TG (mg/dL) 120.61 ± 67.76 146.09 ± 105.23 0.00017
c 0.006 0.009
TG/HDL-C 3.27 ± 2.60 4.13 ± 4.13 0.001
c 0.008 0.011
LAP 44.42 ± 37.72 56.00 ± 49.80 0.0011
c 0.004 0.006
rs3780378 recessive model. ANOVA was performed for normal-distributed data and Welch otherwise. Multiple linear regression analysis was used to adjust for
possible confounding variables. Linear regression analysis was performed with log transformed values for phenotypes deviating from normality. LAP = lipid
accumulation product.
c= Welch p value.
a Age adjusted;
b Age and BMI adjusted.
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mg/dl and HW; and we demonstrated differences in
TG, TG/HDL-C and LAP between genotypes at levels
that take into account multiple testing.
In our study we genotyped only the most significant
variants of a gene wide association study conducted by
Ge et al. Some results had been corroborated in our
sample. The authors found that subjects homozygous
for the major allele of rs3780378 had lower levels of TG
in comparison to subjects homozygous or heterozygous
for the minor allele; and they also failed to find associa-
tion between rs3780378 and obesity related phenotypes
or measurements of IR. Taking into account the results
of both studies, the association between rs3780378 and
TG seems to be relevant and deserves further attention.
Moreover, in our sample, rs3780378 was associated with
categorical and continuous variables related to TG. The
authors also reported association with total cholesterol
and LDL-C. Furthermore, in their cohort, rs7849191
was associated with continuous variables related to obe-
sity. Although these associations are nominal, we should
notice the poor correlation between both results. Such
discrepancies are probably due to different allele fre-
quencies or different LD structure in both populations.
We used estimated haplotype frequencies to assess the
relationship between variation in a 142.8 kb region and
defined phenotypes using SNP genotypes collected on
cases and controls. The effect of combinations of two-
SNP haplotype (rs7849191 and rs3780378 in that order)
was consistent with single locus analysis. Our results
show that carring both protective alleles (haplotype CT),
w o u l db ea s s o c i a t e dw i t hM Sa n dT Gv a l u e su n d e r1 5 0
mg/dl and HW. Furthermore, haplotype analysis of
quantitative metabolic traits seemed to reveal significant
differences in TG, TG/HDL-C and LAP between haplo-
types. Association with MS was significant at levels that
take into account multiple comparisons.
The current results may be related to the role of
inflammation in the development of MS and related traits
such as HW, elevated TG/HDL-C and elevated LAP.
Recent studies suggest that accumulation of inflamma-
tory T-cells in adipose is an early event in obesity and
MS [32,33]. We previously demonstrated in a sample
selected from the same cross-sectional study, that both
TG/HDL-C and LAP, were the majors predictors of MS
[34] LAP and TG/HDL-C could be associated with highly
lipolytic adipose tissue. Adipose tissue with high levels of
lipolysis is an early and critical abnormality in the devel-
opment of cardiovascular disease, DM2 and MS [35].
Pro-inflammatory cytokines negatively regulate insulin
action through phosphorylation of IRS-1 or induction of
SOCS expression [36]. JAK2 is the key mediator of cyto-
kine signaling. Several studies have reported cross talk
between the insulin receptor kinase and JAK signaling
pathways but JAK2 involvement in insulin signaling and
function remains to be investigated [37]. Besides, leptin
can induce expression of SOCS3 and has been proposed
as a possible mechanism for leptin resistance, since it
leads to the inhibition of leptin signaling through the
JAK2/STAT3 pathway.
The current study has some limitations, the sample
size was relatively small and p-values were not corrected
for the number of tests performed. This data should be
viewed as a preliminary source for future studies includ-
ing prospective studies with larger sample size and dif-
ferent ethnic groups.
Conclusions
In conclusion, the present study appears to describe for
the first time significant associations of common var-
iants in JAK2 gene with MS and lipid metabolism disor-
ders, such as HW, TG/HDL-C and LAP. These findings
could be explained by the role of JAK2 in insulin and/or
leptin signaling. The molecular mechanisms that explain
the associations observed are still unknown but
rs7849191and rs3780378 themselves, or SNPs in LD
with rs3780378 may be located in regulatory regions
with potential functional effects.
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